Echinocandin resistance: An emerging clinical problem?

Current Opinion in Infectious Diseases

Volumn 27, Issue 6, 2014, Pages 484-492

  Arendrup, Maiken C ^a   Perlin, David S ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Candida; Echinocandins; Epidemiology; FKS hot spot mutation

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT; FUNGAL PROTEIN;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; GENE MUTATION; HUMAN; KLUYVEROMYCES MARXIANUS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PICHIA KUDRIAVZEVII; REVIEW; SACCHAROMYCES CEREVISIAE; YARROWIA LIPOLYTICA; CANDIDIASIS; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; MUTATION; NUCLEOTIDE SEQUENCE; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TARGETED THERAPY; MUTATION; TREATMENT OUTCOME;

EID: 84927788542     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000111     Document Type: Review

References (59)

1. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110-1122.
2. Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18 (Suppl 7):9-18.
3. Cornely OA, Bassetti M, Calandra T, et al. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 (Suppl. 7):19-37.
4. Hope WW, Castagnola E, Groll AH, et al. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18 (Suppl 7):38-52.
5. Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012; 18 (Suppl 7):53-67.
6. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535.
7. Garcia-Effron G, Katiyar SK, Park S, et al. A naturally occurring proline-toalanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52:2305-2312.
8. Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55:532-538.
9. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-3273.
10. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 2008; 52:2263-2265.
11. Desnos-Ollivier M, Bretagne S, Raoux D, et al. Mutations in the fks1 gene in Candida albicans, C. tropicalis and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the EUCAST method. Antimicrob Agents Chemother 2008; 52:3092-3098.
12. Jensen RH, Johansen HK, Arendrup MC. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother 2013; 57:614-617.
13. Fekkar A, Meyer I, Brossas JY, et al. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother 2013; 57:2380-2382.
14. Desnos-Ollivier M, Moquet O, Chouaki T, et al. Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. J Clin Microbiol 2011; 49:2304-2306.
15. Arendrup MC, Garcia-Effron G, Lass-Florl C, et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSIM27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 2010; 54:426-439.
16. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10:121-130.
17. Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115:4745-4752.
18. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56:126-129.
19. Lewis JS, Wiederhold NP, Wickes BL, et al. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother 2013; 57:4559-4561.
20. Jensen RH, Justesen US, Rewes A, et al. Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei. Antimicrob Agents Chemother 2014; 58:3550-3552.
21. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18:86-90.
22. Matsumoto E, Boyken L, Tendolkar S, et al. Candidemia surveillance in Iowa: emergence of echinocandin resistance. Diagn Microbiol Infect Dis 2014; 79:205-208.
23. Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56:1724-1732.
24. Jensen RH, Johansen HK, Søes LM et al. Posttreatment antifungal resistance among colonising Candida isolates in candidaemia patients: preliminary results from a systematic multicentre study. In Proceedings of the 24th European Congress on Clincial Microbiology and Infectious Diseases, 10-13 May 2014, Barcelona. Abstract 088, p. 45.
25. Shields RK, Nguyen MH, Press EG, et al. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 2013; 57:3528-3535.
26. Jensen RH, Arendrup MC. Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J Clin Microbiol 2011; 49:549-556.
27. Arendrup MC, Perlin DS, Jensen RH, et al. Differential in vivo activity of anidulafungin, caspofungin and micafungin against C. glabrata with and without FKS resistance mutations. Antimicrob Agents Chemother 2012; 56:2435-2442.
28. Castanheira M, Woosley LN, Messer SA, et al. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother 2014; 58:577-580.
29. Shields RK, Nguyen MH, Press EG, et al. Anidulafungin and micafungin minimum inhibitory concentration breakpoints are superior to caspofungin for identifying FKS mutant Candida glabrata and echinocandin resistance. Antimicrob Agents Chemother 2013; 57:6361-6365.
30. Pham CD, Iqbal N, Bolden CB, et al. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014; 58:4690-4696.
31. Ben-Ami R, Garcia-Effron G, Lewis RE, et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis 2011; 204:626-635.
32. Singh-Babak SD, Babak T, Diezmann S, et al. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog 2012; 8:e1002718.
33. Lee KK, MacCallum DM, Jacobsen MD, et al. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother 2012; 56:208-217.
34. Lackner M, Tscherner M, Schaller M, et al. Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment. Antimicrob Agents Chemother 2014; 58:3626-3635.
35. Borghi E, Andreoni S, Cirasola D, et al. Antifungal resistance does not necessarily affect Candida glabrata fitness. J Chemother 2013; 26:32-36.
36. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard-Third edition. CLSI document M27-A3. 2008. Clinical and Laboratory Standards Institute, Pennsylvania, USA.
37. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 2012; 18:E246-E247.
38. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Update 2013; 16:81-95.
39. Marcos-Zambrano LJ, Escribano P, Sanchez C, et al. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 2014; 58:4565-4572.
40. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. EUCAST technical note on candida and micafungin, anidulafungin and fluconazole. Clin Mycoses 2014; 57:377-379.
41. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth informational Supplement. CLSI document M27-S4. 2012. Clinical and laboratory Standards Institute, Pennsylvania, USA.
42. Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013; 19:E343-E353.
43. Shields RK, Nguyen MH, Press EG, et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 2012; 56:4862-4869.
44. Arendrup MC, Pfaller MA. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother 2012; 56:3965-3968.
45. Eschenauer GA, Nguyen MH, Shoham S, et al. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother 2014; 58:1897-1906.
46. Arendrup MC, Rodriguez-Tudela JL, Park S, et al. Echinocandin susceptibility testing of Candida spp. using the EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time and drug lots. Antimicrob Agents Chemother 2011; 55:1580-1587.
47. Pfaller MA, Diekema DJ, Jones RN, Castanheira M. Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida using CLSI methods and interpretive criteria. J Clin Microbiol 2014; 52:3223-3229.
48. Pfaller MA, Messer SA, Diekema DJ, et al. Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. J Clin Microbiol 2014; 52:108-114.
49. Astvad KM, Perlin DS, Johansen HK, et al. Evaluation of caspofungin susceptibility testing by theNewVitek2AST-YS06Yeast Card using a uniquecollection of FKS wild-type and hot spot mutant isolates, including the five most common Candida species. Antimicrob Agents Chemother 2013; 57:177-182.
50. Dudiuk C, Gamarra S, Leonardeli F, et al. Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance. J Clin Microbiol 2014; 52:2609-2614.
51. Pham CD, Bolden CB, Kuykendall RJ, Lockhart SR. Development of a luminex-based multiplex assay for detection of mutations conferring resistance to echinocandins in Candida glabrata. J Clin Microbiol 2014; 52:790-795.
52. De Carolis E, Vella A, Florio AR, et al. Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species. J Clin Microbiol 2012; 50: 2479-2483.
53. Vella A, De Carolis E, Vaccaro L, et al. Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis. J Clin Microbiol 2013; 51:2964-2969.
54. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-2482.
55. Vazquez J, Reboli A, Pappas P, et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an openlabel trial. BMC Infect Dis 2014; 14:97.
56. Nucci M,Queiroz-Telles F, Alvarado-Matute T, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 2013; 8:e59373.
57. Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010; 54: 5042-5047.
58. Pfaller MA, Moet GJ, Messer SA, et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011; 49:396-399.
59. Tortorano AM, Prigitano A, Lazzarini C, et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection 2013; 41:655-662.